This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Digging into the Phase 3 results for Vanda's fanapt (iloperidone) in treating bipolar depression
Ticker(s): VNDAWho's the expert?
Institution: Columbia University
- Associate Professor of Clinical Psychiatry and Director of the Columbia Schizophrenia Research Center (CSRC)
- Research career is investigating novel pharmacological and sensory-based treatments for core neurocognitive dysfunction in schizophrenia.
- Research has demonstrated that NMDAR dysfunction may contribute to underlying neuroplasticity deficits; has also conducted numerous early stage, target engagement biomarker studies with novel therapeutics using neurophysiological and neuroimaging biomarkers.
Interview GoalThis interview will focus on discussing the recent late stage trial results from the Phase III VP-VYV-683-3201 which looks into the use of fanapt (iloperidone) to treat adult patients with acute manic and mixed episodes associated with bipolar I disorder
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
